THIS IS NOT A REQUEST FOR PROPOSALS (RFP) OR A REQUEST FOR QUOTATIONS (RFQ); IT IS STRICTLY A REQUEST FOR INFORMATION (RFI). NEITHER UNSOLICITED PROPOSALS NOR ANY OTHER KINDS OF OFFERS WILL BE CONSIDERED IN RESPONSE TO THIS RFI. NO CONTRACT WILL BE AWARDED PURSUANT TO THIS ANNOUNCEMENT.
1.0 DISCLAIMER: This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future RFQ will not be entertained.
2.0 SUBJECT: WRAIR is the largest and most diverse biomedical research laboratory in the Department of Defense (DoD). The main facility, the Daniel K. Inouye building, is located in Silver Spring, Maryland. Other laboratory and clinical facilities also carry out research studies in Asia, Africa, and Europe through cooperative partnerships with a host of other governments and militaries through the U.S. State Department. WRAIR's greatest resources are the dedicated scientists, clinicians, and support personnel who make up the core of WRAIR today. By integrating basic research and advanced technology for the primary goal of protecting the Warfighter, WRAIR serves as the premier biomedical research organization within the DoD. 3.0 BACKGROUND: The mission of the WRAIR's Bacterial Diseases Branch (BDB) seeks to overcome threats by developing new vaccines, therapeutics, and diagnostics, targeting the most dangerous pathogens through the Multidrug Resistant Organism Repository and Surveillance Network (MRSN), developing an effective diarrheal vaccine, and new antibiotics, including bacteriophages and novel antibiotic drug classes. 4.0 RESPONSE INSTRUCTIONS: Respondents should address the following in their capabilities statement: The purpose for this requirement is for the purchase of a Vitek MS Prime matrix assisted laser desorption ionization - time of flight (MALDI-TOF) mass spectrometry system with compatible Vitek cart and full-service preventive annual maintenance. This system must be compatible with existing Vitek equipment and provide continuity of operation within the BDB laboratory. 5.0 CONTACT INFORMATION: All information regarding Capabilities Statements or any other proprietary information relative to this RFI shall be submitted via email to brenda.i.mena.civ@health.mil no later than 10:00 a.m. E.S.T. on Wednesday, 10 January 2024. The Method of Contractor Selection has not been determined at this Time
.webp)
